Tag Archives: ideas

Emerging Global Advisors To Shut Down 2 ETFs

Emerging market ETF player, Emerging Global Advisors (“EGA”), has decided to cease trading two of its EGShares products on November 2, 2015. The closures reflect a lack of interest in these funds as they represent less than 2% of EGA’s assets. The two EGShares ETFs serve divergent interests and have failed to live up to their investors’ expectations. Let’s examine the underlying reasons for their underperformance: EGShares Brazil Infrastructure ETF (NYSEARCA: BRXX ) BRXX tracks the FTSE Brazil Infrastructure Extended Index focusing on 30 companies that FTSE deems to be representative of infrastructure industries in Brazil. The fund has been overlooked by investors as it has garnered only $8.6 million in assets since its inception in February 2010. Almost all Brazil ETFs have been beaten down lately due to the country’s troubling economy, which is now in a technical recession due to falling GDP, higher inflation and huge public deficit. The economy contracted 1.9% in the second quarter following a 0.7% decline in the first. This marks the worst slowdown for Brazil in nearly three decades (read: Global X to Close These 4 ETFs ). The majority of the railroad and port building projects in Brazil are tied to growth in the country’s oil and mining industry. These infrastructure projects have come to a halt due to plunging oil prices affecting its oil industry and dampening demand for iron ore led by economic slowdown in China. Brazil is the world’s second-largest producer of iron ore and China is the major market for it. These factors have led investors to stay away from this fund. BRXX dropped 47.1% so far this year and lost about 76% in the last five years (as of October 1, 2015) (read: S&P Downgrades Brazil to Junk: ETFs in Focus ). Emerging markets have been out of investors’ favor over the past several months piling up heavy losses. BCHP follows the equally weighted 30 stock EGAI Developed Markets Blue Chip EM Access Index focusing on companies that generate revenues from emerging markets. The fund is almost neglected gathering a meager $4.3 million in assets since its inception in April last year. Domestic strength in the U.S. raising the possibility of a Fed rate hike, lower commodity prices and economic turmoil in China have resulted in a massive sell-off in emerging market stocks in the past few months. This made the fund an unpopular choice among investors. It was down 7.8% in the past one year. Link to the original post on Zacks.com Share this article with a colleague

Exiting A Short VIX Trade

Summary A common question I receive, answered here. An update on the contango and backwardation strategy. Current advice on the VIX. Hello everyone, I hope you have had a profitable month so far. A common question I receive revolves around when to exit a short VIX trade. There really isn’t a common answer to this question but I would be happy to share what I do. Before we begin our discussion I wanted to go over a few things. I believe volatility trading can be done by all different types of investors. I personally follow a very simple method and I know there are many others here that comment with more complex strategies. In reality they all follow the very basic principles of buy low and sell high or in the case of shorting volatility short high cover low. Once you have a good understanding of the basics in volatility, I encourage you to keep increasing your knowledge by reading higher level articles and studies to further your understanding of volatility products. Many times the final piece to understanding lies in the why. Once you can accurately explain why, then you have reached mastery. I have always focused more on the how to than the why. Next summer, I am making a goal to change that and will begin focusing more on the why then the how to. I have spent a great deal of time putting together educational pieces on volatility products and you can view all of those in my Seeking Alpha library. My articles have focused on the basic principles of volatility trading. I started writing to help beginner to moderate level traders who are interested in trading volatility products. When I started trading volatility, not many resources existed for the average investor. I will continuously link back to those pieces and try to promote investor education throughout this transition. One last thing, the comment sections of my articles are always my personal favorite. Even though I don’t respond to every comment, I do read them all and am continuously impressed by what I read. Some of you write such good comments that you should look into actually writing an article or two for Seeking Alpha. Just think about it. I think you would make great contributors. Exiting the short VIX trade A reader suggested strategy for entering a short position in the VIX is posted under this article on contango and backwardation . That article looks into the entry points for shorting the VIX. However, it leaves the exit point up in the air and only causes an exit trade once futures re-enter backwardation from contango. That really isn’t the best overall exit strategy. For the basis of today’s discussion we will use the iPath S&P 500 VIX Short-Term Futures ETN (NYSEARCA: VXX ). Another favorite short of mine is the Proshares Ultra VIX Short-Term Futures (NYSEARCA: UVXY ). VXX invests in front and second month futures contracts. For more on how this ETN operates, click here . If you wait until futures have re-entered backwardation to exit your short position in VXX then you lose some of the profit you could have locked in at a previous date. During the bull market, we have seen extremely long periods of contango which drags VXX down over time. If you are short these shares directly then you may be racking up holding costs by not exiting after a certain period of time. If you are short VXX using options, then you might not have the same concerns. See below for an updated table of the contango and backwardation strategy for VXX. Start dare (enters contango) End date (enters backwardation) Percent Change in VXX 5/21/2012 12/28/2012 -51.56% 12/31/2013 2/25/2013 -16.43% 2/26/2013 6/20/2013 -12.50% 6/21/2013 10/07/2013 -24.72% 10/10/2013 10/15/2013 2.9% 10/16/2013 12/16/2013 -12.02% 12/18/2013 1/30/2014 6.45% 2/7/2014 3/14/2014 5.52% 3/17/2014 4/11/2014 -0.44% 4/14/2014 10/9/2014 -27.37% 10/21/2014 10/22/2014 6.79% 10/23/2014 10/27/2014 2.15% 10/28/2014 12/12/2014 11.08% 12/17/2014 1/6/2014 10.1% 1/8/2015 1/12/2015 9.48% 1/21/2015 1/28/2015 7.6% 2/3/2015 7/8/2015 -35.58% 7/10/2015 8/20/2015 -8.7% 9/16/2015 09/17/2015 7.5% 10/08/2015 volatilityetfs.blogspot.com Table created by Nathan Buehler using historical data from the Intelligent Investor Blog . What you should notice from the above table is the very poor results from 10/21/2014 on. Overall the strategy is profitable but requires very long periods of contango to be highly successful. My exit timing After the VIX has reached a peak and volatility begins to wane, I will set a profit and time target once entering a short position. I prefer not to be in a trade longer than a month. The time frame is more of a risk management tool than about profitability. Generally I set a profit target of around 25%. Now my 25% profit target will not follow the above table because it is a mixture of options and inverse volatility products such as the VelocityShares Daily Inverse VIX Short-Term ETN (NASDAQ: XIV ). To be clear on the time target, I am a worrier. You have to remember I am in a classroom all day and can’t really track what is happening in real time. The shorter I can make my profit target and get out, the happier I am. Waiting for backwardation to reappear can have two side effects. First, you are losing out on your full profit potential. Second, you are trading too often and instead of creating opportunities you are sometimes manufacturing loses. Current Advice Many investors initiated short volatility trades during the past few weeks. I encourage you to follow the above recommendations on exiting the position. Set a profit target and then close out the trade. A focus on U.S. economics should remain as any weakness will send the VIX surging again. So far, especially with jobs data, things continue to look positive. Seasonally volatility will wane after October and into the holiday season. All eyes are going to be on The Fed until liftoff. In case of a trend reversal be ready to lock in profits here. I have a small position in XIV and it has done better than I expected it to. Don’t force any trades here and never chase volatility on a fear of missing out. If you missed this one, wait it out for the next round. I highly appreciate you reading, as always!

I Sold McDonald’s And Then Made These Moves

Summary I sold McDonald’s as I felt the future returns would be diminished. I bought Johnson & Johnson. I made a quick trade in Wells Fargo. I then added to my WEC Energy Group. Last week I published this article which detailed my reasons for selling McDonald’s (NYSE: MCD ). As I stated in the article, it was not easy selling MCD as I had held the stock for 8-years. However, I felt future growth was limited and the high dividend payout would limit future dividend growth. I decided that if I could find a stock with better long-term prospects, I would sell MCD. The stock had to pay a dividend in the vicinity of 3% or more, have good prospects for long term dividend growth, have a solid balance sheet, and have a business set for long-term growth. I keep a list of stocks that I believe are solid businesses and keep an eye on the price action so I am aware when they might become reasonably priced. One of those stocks is Johnson and Johnson (NYSE: JNJ ) and fortunately for me, it recently became reasonably priced. For most investors, JNJ needs no introduction, it is the largest health care company in the world, operating in three segments, consumer, pharmaceutical and medical devices. In the second quarter , consumer sales were $3.5 billion, pharmaceutical sales were $7.9 billion and medical devices had sales of $6.4 billion. Let’s take a look at all three of these segments. Consumer – The consumer segment primarily sells personal care products like nonprescription drugs, skin and hair care products, baby care products, oral care products and first aid products. JNJ products, like Tylenol and Listerine, are well known, but consumer is the smallest segment of JNJ. A few years back, JNJ was embarrassed by a rash of consumer product recalls due to poor safety protocols in the manufacturing plants. The recalls became so bad, that JNJ pulled many of its products from store shelves. After rebuilding their production facilities, JNJ products have slowly returned to the shelf and consumer sales have risen. In the second quarter worldwide consumer sales of $3.5 billion increased 2.3%, with U.S. sales up 2.7%, while outside the U.S. sales grew 2.1%. Look for JNJ to try and build their consumer business globally. Many of their products are regional and JNJ would like to expand their distribution. Here is a comment from JNJ management at a recent conference. ” Coupled with the fact that this business can be globalized, many of the brands have been developed regionally, we now think they can be taken on a more global scale .” Medical Devices – The medical devices segment sells a wide-range of products, such as wound care, surgical sports medicine. women’s health care, products for circulatory disease, blood glucose monitoring, orthopedic joint reconstruction, spinal products and disposable contact lenses. The medical device division recently completed a divestiture of Ortho-Clinical Diagnostics which reduced sales for the second quarter. Worldwide medical devices segment sales of $6.4 billion decreased 4.7%. U.S. sales declined 5.8% while sales outside the U.S. declined 3.9%. Excluding the impact of acquisitions and divestitures, underlying operational growth was 1.4% worldwide with the U.S. up 1.6% and growth of 1.4% outside the U.S. JNJ wants to be number one or number two in all their medical device businesses. Going forward, they want to focus on the orthopedic business as that is where they see the growth. Between 2015 and 2016 they will have 20 new product filings in the medical device business. Pharmaceuticals – The pharmaceutical segment includes products in therapeutics, anti-infective, anti-psychotic, cardiovascular, contraceptive, dermatology, gastrointestinal, hematology, immunology, neurology, oncology, pain management, urology and virology. As you can see, that is a long list and I could list all the drugs they currently have on market and what is about to come to market, but rather than list a bunch of drugs I cannot pronounce, I feel it is more important to share this fact. JNJ believes it will file 10 new drug filings by 2019, each with the potential to achieve $1 billion in annual sales. Here is a quote from JNJ’s second quarter earnings call . ” Our focused R&D strategy and commitment to driving launch excellence to ensure broad access and reimbursement has really come together to make a difference for patients and have this well-positioned to continue to drive above industry compound annual growth rate over the next several years. Fueled by seven of our recently launched products that we expect will each exceed $1 billion in sales this year and the more than 10 new products we plan to file by 2019 that each have $1 billion plus potential of their own based on their transformational potential to treat significant unmet medical needs worldwide .” In the second quarter worldwide sales of $7.9 billion increased 1% with U.S. sales down 1.5% and sales outside the U.S. up 3.8%. New competitors in hepatitis C and a divestiture impacted sales results. Why I am Confident in JNJ Going Forward – All the information I gave you concerning the various segments of JNJ business is interesting, but that is not why I bought the stock. I bought the stock for the following reasons.. The entire world population is getting old and in need of increased medical care. I like to buy stocks that have an overriding theme that will increase their chance for success. In JNJ’s case, their unique broad spectrum of health care products makes them an excellent candidate to benefit from the aging world population. Here are just a few facts highlighting why JNJ is likely to benefit from demographic trends. The United Nations states population aging is unprecedented, without parallel in human history and the 21st century will see even more rapid aging than did the previous century. The global share of older people (aged 60 and over) increased from 9.2 percent in 1990 to 11.7 percent in 2013 and will continue to grow to 21.1% in 2050. In the U.S. the older population-persons 65 years or older-numbered 44.7 million in 2013 (the latest year for which data is available). They represented 14.1% of the U.S. population, about one in every seven Americans. By 2060, there will be about 98 million older persons, more than twice their number in 2013. People 65+ represented 14.1% of the population in the year 2013 but are expected to grow to be 21.7% of the population by 2040. The increased number of persons over 65 years will potentially lead to increased health-care costs. The health-care cost per capita for persons over 65 years in the United States and other developed countries is three to five times greater than the cost for persons under 65 years, and the rapid growth in the number of older persons, coupled with continued advances in medical technology, is expected to create upward pressure on health- and long-term–care spending. One million Americans a year are getting total joint replacement. That figure is expected to grow to four million over the next 20-years. Global annual spending on cancer drugs has hit $100bn for the first time By 2021, annual prescription drug spending will nearly double, to $483.2 billion Health spending growth in the United States is projected to average 5.8 percent for 2014-24, reflecting the Affordable Care Act’s coverage expansions, faster economic growth, and population aging. Those are just a few facts, I could add more, but to me, it is obvious that as the world ages, health care will be a fast growing sector. I am confident, that JNJ, with its over 250 operating companies across the globe, will share in that growth. Why JNJ over McDonald’s – When comparing the two companies it seemed obvious to me, that JNJ was the financially stronger company and the company more likely to grow its business and dividend in the future. Let’s compare the two companies. All numbers are from Yahoo finance. Category JNJ MCD Price to earnings 16.75 23.95 Price to earnings growth 3.10 3.25 Price to book 3.70 9.05 Total cash $33.95B $4B Cash per share $12.26 $4.25 Debt $19.31B $17.9B Debt to equity 27.14 169.51 Yield 3.17 3.36 Dividend payout ratio 50.2% 77.96% Operating cash flow 17.09B 6.55B I think any fair-minded observer would look at those numbers and say JNJ is the more financially sound company and the company more likely to reward shareholders going forward. At a recent Morgan Stanley conference, JNJ CFO Dominic Caruso said this about the large amount of cash that is on the balance sheet. ” So I think it’s safe to say, we have sufficient capital to put to use, we’re going to put it to use. It’s going to be in a value creating acquisition, or in share buybacks ” So we have two companies. MCD which may be cash challenged, or JNJ which is sitting on a pile of cash. We have JNJ selling at a P/E under 17 and MCD selling for over 23. We have JNJ which has raised it’s dividend 6% and 7% the last two years and we have MCD which has raised it’s dividend 5% the last two years. We have JNJ which saw earnings per share grow from $3.49 in 2011 to $5.70 in 2014 and we have MCD which saw earnings fall from $5.27 in 2011 to $4.82 in 2014. After considering all that information, on September 28th, I sold MCD for $97.57 and bought a full position in JNJ for $90.41. I expect to hold forever, or until the business deteriorates. I expect JNJ to grow slowly, benefiting from the demographic trends and JNJ’s diverse health care related products. I also expect the dividend to grow steadily. Next Move McDonald’s was the second biggest position in my portfolio, so selling it freed up a large sum of cash. Even though I bought a full position in JNJ, I still had cash left over from the sale, in addition to cash that had built up in my account from the recent quarterly dividends. As I sat on the cash contemplating what to do with it, I saw a short term situation develop which I took advantage of. On Friday, October 2nd, the Labor Department announced a very disappointing jobs number. When I saw the jobs number, I knew the number was very disappointing and I knew traders would determine any Federal Reserve rate increase, which many thought was coming soon, would be delayed. Based on that, I had a hunch the banks would take a pounding at the open, as investors would determine the banks interest rate spreads, which everyone thought would be improving with a rate increase, would now be further in the future. As I expected, the market opened down big and the banks were the worse performers. I thought this was very short-sighted and an overreaction. Banks were in no worse shape on October 2nd than they were on October 1st. So I took the cash funds in my account and bought Wells Fargo (NYSE: WFC ) for $49.60 shortly after the open. This was a short-term trade, not an investment. I have sworn off banks as an investment as it seems every five years or so, they have some sort of crisis. Fortunately for me, before the day was over, WFC was back above $51.00 and closed at $51.26. I sold WFC on October 7th for $52.56, a quick gain of approximately 6%. The 6% gain added a little more funds to my account, so on October 7th, after selling the Wells Fargo shares, I bought shares in WEC Energy Group (NYSE: WEC ), formerly Wisconsin Energy. I paid $51.88 per share. I began building a position in WEC in July, when I made two purchases, one for $45.10 and another for $46.34. Those two purchases amounted to a little bit more than a half position. With the latest purchase, I now have about an 85% position at a cost basis of $47.63. I imagine I will complete the position before the end of the year. The company, formerly known as Wisconsin Energy, recently purchased Intergys Energy another Midwest utility. The combined company is now known as WECEnergyGroup. WEC is deserving of its own article as there is a lot I would like to say, but briefly let me mention this. WEC provides electricity and natural gas service to 4.4 million customers across four states, Wisconsin, Illinois, Michigan and Minnesota. They are the eighth largest natural gas distribution company in the country and among the 15 largest investor owned utilities in the country. WEC currently yields 3.5% and investors can expect dividend growth of 6-8% a year, in-line with earnings growth. I think WEC is an excellent, financially sound, utility which has several unique characteristics that differentiates it from other utilities. I will expand on WEC in a future article, but suffice to say, I intend to hold WEC forever, or until the business deteriorates. The End Result When all was said and done, I had sold McDonald’s, a long time holding and purchased Johnson and Johnson, a dividend stalwart, that had become attractively priced. I then made a quick purchase and sell of Wells Fargo that resulted in a small profit. Subsequently, I purchased additional shares in WEC Energy Group. So I now own a stock, JNJ, that, in-my-opinion, is a better value and has better long term prospects than MCD, which I previously owned. I also was able to purchase additional shares in WEC Energy Group a stock I am currently building a position in. In addition, the dividends I get from the shares I bought in JNJ and WEC will be slightly more than the dividends I was getting from MCD. Investing is about maximizing your investable cash. I believe in long-term investing, however, at times, there may be a company that offers better value, better growth, and/or better dividend growth, than the stock you own. In that case, selling a stock that you have owned for a long time makes sense. That is the situation I recently saw and that is the action I took. Only time will tell how it works out.